A

Aurinia Pharmaceuticals

D
AUPH
USD
0.91
(12.2642%)
Market Closed
235,470.00
Volume
0.06092
EPS
-
Div Yield
-23.800000
P/E
1,191,114,813.42
Market Cap
Today
10.9927%
1 Week
15.374%
1 Month
21.962%
6 Months
62.695%
12 Months
0.483%
Year To Date
-7.444%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
D
DVAX
-0.29
(-2.3577%)
USD
S
SRPT
-7.62
(-5.9531%)
USD
L
LGND
12.92
(11.0598%)
USD
A
ACAD
1.42
(8.993%)
USD
B
BMRN
0.785
(1.1869%)
USD
X
XLRN
(%)
USD
C
CRSP
1.15
(2.2656%)
USD
E
EDIT
-0.11
(-3.3537%)
USD
B
BLUE
-0.0615
(-14.0764%)
USD
R
RARE
-0.1
(-0.1979%)
USD

Title:
Aurinia Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
Do you need help or have a question?
Contact Us